All News

The FDA has accepted a new supplemental biologics license application for pembrolizumab, an anti-PD-1 therapy, as a single agent for the treatment of patients with advanced endometrial carcinoma that is microsatellite instability-high or mismatch repair deficient, who have diseased progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.

In last month’s Legally Speaking, we published “Health care fraud exposed” by James M. Shwayder, MD, JD. It is disturbing in its details but exposes fraud and medical malpractice that went on for years. The ob-gyn at the center of it, Javaid Perwaiz, was recently sentenced to 59 years in prison.

Even with these recommendations, women commonly ask questions about alcohol consumption and breastfeeding such as “Should I pump and dump if I have a glass of wine?” and “Do I just wait until it has passed through my system?” This month, experts Susan Crowe, MD, and Tricia Wright, MD, MS, provide the needed insight—with as much data as are available on this topic.